Undetected tuberculosis at enrollment and after hospitalization in medical and oncology wards in Botswana.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
11
2018
accepted:
30
06
2019
entrez:
12
7
2019
pubmed:
12
7
2019
medline:
27
2
2020
Statut:
epublish
Résumé
Cancer patients are at higher risk of tuberculosis (TB) infection, especially in hospital settings with high TB/HIV burden. The study was implemented among adult patients admitted to the largest tertiary-level referral hospital in Botswana. We estimated the TB prevalence at admission and the rate of newly diagnosed TB after hospitalization in the medical and oncology wards, separately. Presumptive TB cases were identified at admission through symptom screening and underwent the diagnostic evaluation through GeneXpert. Patients with no evidence of TB were followed-up until TB diagnosis or the end of the study. In the medical and oncology wards, four of 867 admitted patients and two of 240 had laboratory-confirmed TB at admission (prevalence = 461.4 and 833.3 per 100,000, respectively.) The post-admission TB rate from the medical wards was 28.3 cases per 1,000 person-year during 424.5 follow-up years (post-admission TB rate among HIV-positive versus. -negative = 54.1 and 9.8 per 1,000 person-year, respectively [Rate Ratio = 5.5]). No post-admission TB case was detected from the oncology ward. High rates of undetected TB at admission at both medical and oncology wards, and high rate of newly diagnosed TB after admission at medical wards suggest that TB screening and diagnostic evaluation should target all patients admitted to a hospital in high-burden settings.
Identifiants
pubmed: 31295315
doi: 10.1371/journal.pone.0219678
pii: PONE-D-18-33720
pmc: PMC6623960
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0219678Subventions
Organisme : NIAID NIH HHS
ID : K01 AI118559
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA230170
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI028697
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI097045
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMJ. 2018 Aug 23;362:k2738
pubmed: 30139910
J Thorac Oncol. 2011 Jan;6(1):32-7
pubmed: 21150470
Clin Infect Dis. 2006 Jun 1;42(11):1592-5
pubmed: 16652317
J Infect. 2017 Jun;74(6):590-598
pubmed: 28366685
Int J Tuberc Lung Dis. 2012 Dec;16(12):1605-12
pubmed: 23131257
Cancer. 2011 Feb 1;117(3):618-24
pubmed: 20886634
Clin Infect Dis. 2016 Dec 16;64(5):635-644
pubmed: 27986665
Clin Respir J. 2014 Oct;8(4):375-81
pubmed: 24345074
BMC Infect Dis. 2014 Jul 22;14:409
pubmed: 25047744
Int J Tuberc Lung Dis. 2013 Aug;17(8):1049-55
pubmed: 23827029
J Bras Pneumol. 2013 Jun-Aug;39(4):484-9
pubmed: 24068271
Int J Cancer. 2009 Dec 15;125(12):2936-44
pubmed: 19521963
Lancet Infect Dis. 2010 Feb;10(2):93-102
pubmed: 20113978
Int J Tuberc Lung Dis. 2014 Sep;18(9):1026-33
pubmed: 25189548
BMC Infect Dis. 2017 Dec 1;17(1):739
pubmed: 29191155
Eur Respir J. 2017 Aug 24;50(2):
pubmed: 28838977
South Asian J Cancer. 2012 Jul;1(1):36-42
pubmed: 24455507
Curr HIV/AIDS Rep. 2013 Sep;10(3):264-72
pubmed: 23824469
Infect Control Hosp Epidemiol. 2014 May;35(5):534-7
pubmed: 24709722
Cancer. 2004 Dec 15;101(12):2713-21
pubmed: 15547933
Med Arch. 2017 Jun;71(3):212-214
pubmed: 28974836